arrow
D

Daijiro Harada

Okayama University
H指数:22
被引数:2,397

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study

携带EGFR突变非小细胞肺癌患者经第一线奥希替尼治疗后早期疾病进展的循环肿瘤DNA:ELUCIDATOR多中心前瞻性观察研究

2025-04-050
OAAI
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

吉非替尼诱导联合化放疗在EGFR突变型III期非小细胞肺癌中的五年结果:LOGIK0902/OLCSG0905 II期研究

2025-02-050
OA
Updated results of a prospective observational multicenter study on resistance mechanisms to osimertinib using circulating tumor DNA analyses in EGFR-mutated non- small cell lung cancer patients (ELUCIDATOR study)
2024-03-220
PRE
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer
2024-01-095
PRE
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)
2024-01-021
OAAI
Plant GARDEN: a portal website for cross-searching between different types of genomic and genetic resources in a wide variety of plant species
2023-08-126
OAAI
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression

对letter re的回应: 抗生素对非小细胞肺癌患者免疫检查点抑制剂疗效的影响因PD-L1表达而异

2021-11-010
PREAI
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)

贝伐单抗联合铂类化疗治疗晚期非鳞状非小细胞肺癌: 一项随机、开放标签2期研究 (CLEAR)

2021-07-014
OAAI
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression

抗生素对非小细胞肺癌患者免疫检查点抑制剂疗效的影响基于PD-L1表达的差异

2021-05-0145
PREAI
Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced NoneSmall Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol
2017-03-015
PREAI
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403
2017-03-019
PREAI